Carmell Therapeutics Corporation (CTCXW) Comparison with companies in other sectors?

Carmell Therapeutics Corporation has a share price of 20.91M. You can analyze Carmell Therapeutics Corporation (CTCXW) competitors across different market sectors through stock heatmaps.

What are CTCXW's NET and operating margins?

Carmell Therapeutics Corporation (CTCXW) operating margin is around -9.14, and net profit margin is approximately -15.34 as of the latest reports.

In what way does CTCXW's earnings per share (EPS) trend reflect its financial momentum?

Carmell Therapeutics Corporation (CTCXW) EPS is N/A (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Carmell Therapeutics Corporation is N/A, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Carmell Therapeutics Corporation?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Carmell Therapeutics Corporation like P/E which is -0.06, P/B which is -0.15, and PEG which is -0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Carmell Therapeutics Corporation

CTCXW•NASDAQ

Healthcare

Biotechnology

$0.03

$-0.02(-45.40%)

Fundamental Analysis of Carmell Therapeutics Corporation (CTCXW)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

P/E Ratio

ROE

2.47%

Net Margin

-15.34%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$558.17K

Shares OutstandingTotal number of shares issued

$20.91M

Book Value/ShareNet worth per share

$-0.18

Revenue/ShareAnnual revenue per share

$0.03

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

Net MarginNet income as percentage of revenue

-1534.44%

Operating MarginOperating income as percentage of revenue

-914.07%

ROEReturn on shareholders' equity

246.61%

ROAReturn on total assets

-257.79%

ROCEReturn on capital employed

157.12%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.19

Cash/ShareCash and equivalents per share

$0.04

FCF YieldFree cash flow as percentage of market cap

-728.47%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for CTCXWFinancial Ratios Analysis details for CTCXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CTCXWSector Benchmarking details for CTCXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Carmell Therapeutics Corporation Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Carmell Therapeutics Corporation. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Carmell Therapeutics Corporation's unique business strengths and challenges.

Key Financial Metrics for Carmell Therapeutics Corporation

For Carmell Therapeutics Corporation, essential financial indicators include EPS -, PE -, and ROE 2.47. These key ratios reveal insights into Carmell Therapeutics Corporation's profitability, valuation, and operational health. Understanding these metrics enables you to compare Carmell Therapeutics Corporation with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Carmell Therapeutics Corporation

Metrics like Net Margin -1534.44% and ROA -257.79% shed light on how well Carmell Therapeutics Corporation is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Carmell Therapeutics Corporation can sustain its operations and continue growing in the future.

Valuation and Market Position of Carmell Therapeutics Corporation

Using ratios such as P/B Ratio -0.15 and PEG Ratio -0.00, investors can assess whether Carmell Therapeutics Corporation is appropriately valued based on its financials and growth potential. These figures, combined with Carmell Therapeutics Corporation's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Carmell Therapeutics Corporation

Financial health indicators, such as Debt/Equity Ratio -0.11 and Cash Flow $-0.19, provide a snapshot of Carmell Therapeutics Corporation's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Carmell Therapeutics Corporation, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Carmell Therapeutics Corporation

Investing in Carmell Therapeutics Corporation based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Carmell Therapeutics Corporation focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;